We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Read MoreHide Full Article
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL - Free Report) and Hims & Hers Health, Inc. (HIMS - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Omnicell has a Zacks Rank of #2 (Buy), while Hims & Hers Health, Inc. has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that OMCL likely has seen a stronger improvement to its earnings outlook than HIMS has recently. But this is just one piece of the puzzle for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
OMCL currently has a forward P/E ratio of 23.87, while HIMS has a forward P/E of 81.15. We also note that OMCL has a PEG ratio of 2.78. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. HIMS currently has a PEG ratio of 7.75.
Another notable valuation metric for OMCL is its P/B ratio of 1.49. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, HIMS has a P/B of 15.35.
Based on these metrics and many more, OMCL holds a Value grade of B, while HIMS has a Value grade of D.
OMCL has seen stronger estimate revision activity and sports more attractive valuation metrics than HIMS, so it seems like value investors will conclude that OMCL is the superior option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL - Free Report) and Hims & Hers Health, Inc. (HIMS - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Omnicell has a Zacks Rank of #2 (Buy), while Hims & Hers Health, Inc. has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that OMCL likely has seen a stronger improvement to its earnings outlook than HIMS has recently. But this is just one piece of the puzzle for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
OMCL currently has a forward P/E ratio of 23.87, while HIMS has a forward P/E of 81.15. We also note that OMCL has a PEG ratio of 2.78. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. HIMS currently has a PEG ratio of 7.75.
Another notable valuation metric for OMCL is its P/B ratio of 1.49. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, HIMS has a P/B of 15.35.
Based on these metrics and many more, OMCL holds a Value grade of B, while HIMS has a Value grade of D.
OMCL has seen stronger estimate revision activity and sports more attractive valuation metrics than HIMS, so it seems like value investors will conclude that OMCL is the superior option right now.